CITRIS Foundry alum Aluna recently received clearance from the U.S. Food and Drug Administration (FDA) for its asthma management device and platform. Aluna helps patients, particularly pediatric patients, better manage their asthma by recording and tracking lung function scores. Better tracking of lung function can help prevent asthma attacks and flare-ups, resulting in controlled and managed asthma.
“This FDA clearance is a watershed moment for our company and for asthmatics everywhere. As asthmatics ourselves, my co-founders and I are personally and acutely aware of the daily struggle of living with asthma. Children often struggle to communicate the symptoms that they are experiencing or recognize certain triggers that should alter their behavior. Now, with our device, kids have the ability to instantly measure their lung health, track and monitor ongoing symptoms. They can also see their data over time – ultimately helping them better self-manage their asthma. We believe that the Aluna will help asthmatics everywhere better manage their condition, empowering them to live life to its fullest. Use of Aluna will enable more informed and open dialog between patients and their doctors about how to best cope with this chronic disease,” says Charvi Shetty, Aluna Co-Founder and CEO
Aluna plans a consumer launch in the Spring of 2020. Though a prescription is not required, Aluna recommends consulting with one’s physician when using the Aluna platform.